DOACs seem more effective than low molecular weight heparins for the prevention of symptomatic venous thromboembolism in non-cardiac surgery
Direct acting oral anticoagulants (DOACs) are more effective for the prevention of symptomatic venous thromboembolism in comparison to prophylactic dosing with low molecular weight (LMW) heparins. However, DOCAs are no more effective than high dose LMW heparins in non-cardiac surgical patients. This was the conclusion of a systemic review and network meta-analysis by researchers from the Department of Health Research Methods, Evidence, and Impact, McMaster University, Ontario, Canada
A venous thromboembolism is a significant problem in the peri-operative period with the potential to increase patient morbidity, mortality and associated health care costs. Typically, a venous thromboembolism presents as either a deep vein thrombosis or a pulmonary embolism. Although both the DOACs and LMW heparins are recognised as convenient and effective prophylaxis regimens against venous thromboembolism for at-risk surgical patients, there is a lack of direct and comparative evidence to guide clinician’s choice. Nevertheless, it seems that in practice, one survey of thrombosis experts revealed how 85.9% would recommend the use of LMW heparins.
With a level of uncertainty over the relative benefits of either DOACs or LMW heparins, the Canadian team undertook a systematic review and network meta-analysis of existing randomised controlled trials in which there was a comparison of LMW heparins, DOACs and no active treatment for thromboprophylaxis in patients undergoing non-cardiac surgery. The researchers suspected that the relative efficacy of the two therapeutic options would be similar across a range of surgical settings and hence used a network meta-analysis to enable a comparison to be made where there was an absence of direct comparative studies.
The team included randomised trials in adult patients (> 18 years of age) undergoing non-cardiac surgery, including general, urological, gynaecological, orthopaedic and thoracic procedures. They searched for studies in which the use of low dose LMW heparins (e.g., enoxaparin 40 mg daily), high dose (e.g., enoxaparin 30 mg twice daily) and DOACs had been employed. The outcome of interest was a reduction in symptomatic pulmonary embolism and/or deep vein thrombosis and they considered major bleeding as the primary anticipated harm.
DOACs and symptomatic venous thromboembolism
A total of 68 eligible studies with 45,445 patients were included in the analysis. In 25 trials with 30, 230 patients, 0.78% had a symptomatic venous thromboembolism and in 61 studies, 0.25% had a pulmonary embolism.
Overall and compared to no treatment, all three interventions were associated with a significant reduction in the odds of symptomatic venous thromboembolism. For example, DOACs (OR = 0.17, 95% CI 0.07 – 0.41), LMW heparins (OR = 0.33) and high dose LMW heparins (OR = 0.19).
When the different treatments were compared in the network meta-analysis, the use of DOACs was associated with a significant reduction in symptomatic venous thromboembolism compared to LMW heparin (odds ratio, OR = 0.53, 95% CI 0.32 – 0.89, p = 0.02). However, there was no significant difference compared to high dose LMH heparin (OR = 0.93, 95% CI 0.51 – 1.71).
In terms of bleeding, both DOACs and both doses of LMW heparins were associated with an increased risk of a major bleed. The risk was approximately two-fold higher for both DOACs and LMW heparins (e.g., OR = 2.01 for DOACs).
The authors concluded that both DOACs and LMW heparins are effective for symptomatic venous thromboembolism in non-cardiac surgery and that the former class of drugs are probably more effective and LMW heparins when used at the standard prophylactic dose.
Marcucci M et al. Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials BMJ 2022